News | September 08, 2021
RenovoRx receives New 510(k) clearance from US FDA
The company’s RenovoCath Delivery System designed for targeted treatment of solid tumours
The company’s RenovoCath Delivery System designed for targeted treatment of solid tumours
Labetalol hydrochloride injection USP is indicated for the control of blood pressure in severe hypertension.
Zydus’ Sitagliptin base contains the active moiety Sitagliptin in a different form than used in the branded reference product, Januvia (Sitagliptin Phosphate)
Metronidazole Gel USP, 1% is indicated for the topical treatment of inflammatory lesions of rosacea
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
The drug is also intended for the treatment of glioblastoma multiforme
The company will manufacture the products at its US FDA approved oral dosage facility at Goa in India
The product will be available in 500 mg/2.5 mL and 1 g/5 mL vials
The Evolut FX TAVR system is used for treatment of symptomatic severe aortic stenosis and it has features that enhance ease-of-use and predictable valve deployment
New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis. Heart failure accounts for more than one million hospitalisations a year in the US
Subscribe To Our Newsletter & Stay Updated
